Replies to post #38442 on Pluristem Therapeutics Inc (PSTI)

[skitahoe]

While I believe approval for PLX-PAD in Covid-19 should bring us a billion dollar market cap, I'm thinking the terms of the EUA limit what we can be paid for the drug, as well as the number, at least initially. I haven't seen the EUA in print, I'm uncertain where the limit of 100 is imposed, but if it is, and results look positive, it should become unlimited.

I understand that drugs being supplied by BP for Covid are at cost. If that's the terms that PSTI has to agree to in order to get the EUA it will still give the company great credibility, and should result in future profits.

I would hope they have sufficient drug staged that in days they can dose 100 patient under the EUA, if that's the case, by the end of September, perhaps sooner, we should see the program expanded as patients come off ventilator. I look forward to seeing more about how this is happening.

Gary

[zzaatt]

Thanks for the clarification!

The EAP is in fact more significant in expanding the scope of use. I am however puzzled by the 100 limit. Maybe the idea is that Pluristem should be able to show significant benefit outside the highly regulated clinical trial, and thus will be eligible for reconsideration after the 100 th patient treated. That's my optimistic and unsubstantiated hope,

Regards,
zzaatt.